Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years or older~* Histological confirmation of supratentorial GBM~* KPS \> 60~* Neurological function 0 or 1~* Adequate bone marrow as defined below:~* absolute neutrophil count (ANC) \> 1500 cells/mm3~* platelets \> 100,000 cells/mm3~* hemoglobin \> 10g/dl~* Adequate renal function as defined below:~* BUN \< 25mg/dl within 14 days prior to study registration~* creatinine of 63 to 103 umol/L within 14 days prior to study registration~* Adequate hepatic function as defined below:~* Bilirubin of 3 to 21 umol/L within 14 days prior to study registration~* ALT \& AST \< 3xnormal range within 14 days prior to study registration~* Neoadjuvant TMZ to start within 3 weeks of surgery/biopsy if no resection was deemed feasible~* A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed preoperatively and postoperatively.~* History, physical and neurological examination within 14 days prior to study registration.~* For females of child-bearing potential, negative pregnancy test within 72 hours prior to starting TMZ.~* Able to sign an informed study-specific consent~Exclusion Criteria:~* Margin of contrast-enhanced residual mass closer than 15mm from the optic chiasm or optic nerves.~* Prior invasive malignancy, unless disease-free for \>3years~* Recurrent or multifocal GBM~* Severe co-morbidities such as~* unstable angina~* transmural myocardial infarction within 6 months~* COPD at the time of registration~* Hepatic insufficiency~* Bacterial or fungal infection requiring IV antibiotics at the time of registration~* Acquired Immune Deficiency Syndrome (AIDS)~* Major medical illnesses or psychiatric impairments~* Pregnant women or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide, Accelerated Hypofractionated RT (Type: EXPERIMENTAL): Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).